Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin

Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin

Abstract Background Nanoliposomal irinotecan plus fluorouracil/leucovorin (5-FU/LV) is a standard second-line therapy for patients with pancreatic cancer. Identification of biomarkers is important to determine appropriate treatment strategies. We investigated the clinical practice outcomes and bioma...

Full description

Bibliographic Details
Main Authors:	Takeshi Kawakami, Akiko Todaka, Kotoe Oshima, Kunihiro Fushiki, Satoshi Hamauchi, Takahiro Tsushima, Tomoya Yokota, Yusuke Onozawa, Hirofumi Yasui, Kentaro Yamazaki
Format:	Article
Language:	English
Published:	BMC 2023-01-01
Series:	BMC Cancer
Subjects:	Pancreatic cancer Nanoliposomal irinotecan GPS NLR Biomarker
Online Access:	https://doi.org/10.1186/s12885-023-10542-w

Similar Items

Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer
by: Ryoji Takada, et al.
Published: (2023-07-01)

Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan
by: Ko AH
Published: (2016-03-01)

Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel
by: Taro Shibuki, et al.
Published: (2024-07-01)

Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer: a multicenter observational study (NAPOLEON-2)
by: T. Shirakawa, et al.
Published: (2025-06-01)

A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer
by: Tomoko Kodama, et al.
Published: (2024-05-01)

IRINOTECAN, FLUOROURACIL AND LEUCOVORIN IN PATIENTS WITH METASTATIC COLORECTAL CANCER
by: Deyan Davidov
Published: (2008-09-01)

Ischemic Colitis of the Transverse Colon Induced by 5-Fluorouracil, Leucovorin, and Irinotecan: A Case Report
by: Fezzeh Elyasinia, et al.
Published: (2022-06-01)

Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study
by: L. Perkhofer, et al.
Published: (2019-10-01)

5-Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan as a Potential Standard for Second-line Therapy in Extrapulmonary Neuroendocrine Carcinomas
by: I-Wei Ho, et al.
Published: (2024-12-01)

Remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy in urothelial cancer of the renal pelvis: a case report
by: Takuya Tsujino, et al.
Published: (2017-04-01)

Real-world data of anamorelin in advanced gastrointestinal cancer patients with cancer cachexia
by: Ari Nishimura, et al.
Published: (2024-08-01)

EGFR-targeting polydopamine nanoparticles co-loaded with 5-fluorouracil, irinotecan, and leucovorin to potentially enhance metastatic colorectal cancer therapy
by: Rania Djermane, et al.
Published: (2024-11-01)

Encapsulation of Vitamins Using Nanoliposome: Recent Advances and Perspectives
by: Masoud Aman Mohammadi, et al.
Published: (2023-01-01)

Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study
by: Se Jun Park, et al.
Published: (2021-11-01)

Determination of Extravasation Effects of Nal-Iri and Trabectedin and Evaluation of Treatment Options for Trabectedin Extravasation in a Preclinical Animal Model
by: Omar Keritam, et al.
Published: (2022-06-01)

The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma
by: Letizia Procaccio, et al.
Published: (2023-07-01)

Results of using 3-component regimen TEGOXIRI (tegafur, oxaliplatin, irinotecan) ± Leucovorin in patients with advanced colorectal cancer
by: N. V. Dobrova, et al.
Published: (2019-12-01)

Metastatic Pancreatic Cancer: Current Treatment Options for Swiss Patients
by: Sara De Dosso, et al.
Published: (2021-06-01)

Preclinical toxicity assessment of anionic nanoliposomes
by: Amir Abbas Momtazi-Borojeni, et al.
Published: (2024-01-01)

Increased response of oxaliplatin or irinotecan on chemosensitivity to 5-fluorouracil in patients with colorectal cancer
by: Se Na Cho, et al.
Published: (2014-06-01)

Relationship between neutropenia caused by nanoliposomal irinotecan/fluorouracil/leucovorin and treatment outcomes in the NAPOLEON-2 study (NN-2301)
by: Tomonori Araki, et al.
Published: (2025-01-01)

Production and Evaluation of Nanoliposomes Loaded with Capparis spinosa Extract
by: Masoumeh Salamatian, et al.
Published: (2023-03-01)

Transnasal nimodipine-loaded mucoadhesive nanoliposomes: Preparation and in-vitro evaluation
by: Nozad Rashid Hussein, et al.
Published: (2019-08-01)

Preparation of Benzothiazolyl-Decorated Nanoliposomes
by: Spyridon Mourtas, et al.
Published: (2019-04-01)

Application of Nanoliposomes Containing Nisin and Crocin in Milk
by: Mohammad Yousefi, et al.
Published: (2023-01-01)

BEVACIZUMAB IN COMBINATION WITH IRINOTECAN IN THE TREATMENT OF RECURRENT GLIOBLASTOMAS
by: D. R. Naskhletashvili, et al.
Published: (2015-04-01)

5-Fluorouracil and irinotecan (SN-38) have limited impact on colon microbial functionality and composition in vitro
by: Eline Vanlancker, et al.
Published: (2017-11-01)

ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer
by: S. Lindsey Davis, et al.
Published: (2022-10-01)

Nanoparticles and Nanoliposomes for Hair Growth Serum
by: Arif Arismunandar, et al.
Published: (2024-08-01)

Microbiota-Host-Irinotecan Axis: A New Insight Toward Irinotecan Chemotherapy
by: Bei Yue, et al.
Published: (2021-10-01)

High‐Load Core@Shell Nanocarriers with Irinotecan and 5‐Fluorouracil for Combination Chemotherapy in Colorectal Cancer
by: Silke Notter, et al.
Published: (2024-11-01)

Physicochemical Properties of Nanoliposomes Encapsulating Grape Seed Tannins Formed with Ultrasound Cycles
by: Angela Monasterio, et al.
Published: (2024-01-01)

Stabilization of caffeine-loaded nanoliposomes via chitosan coating and spray drying for application in food products
by: Zahra Mehrabi-Khozani, et al.
Published: (2024-12-01)

FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational study
by: Satoshi Kobayashi, et al.
Published: (2023-02-01)

Breaking the selectivity-uptake trade-off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi-tier cancer targeting
by: Barry J. Liang, et al.
Published: (2020-01-01)

Preparation, Characterization and Cytotoxic Studies of Cisplatin-containing Nanoliposomes on Breast Cancer Cell Lines
by: Fateme Mohammadinezhad, et al.
Published: (2023-07-01)

Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a real-world study
by: Amol Gupta, et al.
Published: (2023-08-01)

Features of lyophilization of a nanoliposomal drug
by: V. G. Pushkar, et al.
Published: (2016-10-01)

Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity
by: Marwa S. Mahdy, et al.
Published: (2023-03-01)

Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer
by: Höhler Thomas, et al.
Published: (2004-07-01)